ARGX-119

BIOLOGICAL4 trials

Sponsors

Argenx, argenx

Conditions

Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)CMSCongenital Myasthenic SyndromeHealthy Volunteers

Phase 1

A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

CompletedNCT05670704

argenxHealthy Volunteers

Start: 2023-02-21End: 2024-08-08Updated: 2024-08-23

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

Active, not recruitingNCT06436742

argenxCMS, Congenital Myasthenic Syndrome

Start: 2024-09-24End: 2028-01-24Updated: 2026-07-24

Phase 2

A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

TerminatedNCT06441682

argenxAmyotrophic Lateral Sclerosis

Start: 2024-10-23End: 2026-08-12Updated: 2026-09-15

A Phase 2a, Double-Blinded, Randomized, Placebo-Controlled, and Active-Treatment Extension Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Participants With Amyotrophic Lateral Sclerosis

RecruitingCTIS2024-511318-19-00

ArgenxAmyotrophic Lateral Sclerosis (ALS)

Start: 2024-10-23Target: 49Updated: 2025-09-08